Physician profile
Thomas U Tan
NPI 1285708347
$13,584.94
in general payments reported to CMS, 2019-2025
43 companies · $95.47 in 2025
The $95.47 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,898 · 2020: $1,705 · 2021: $3,091 · 2022: $2,647 · 2023: $2,740 · 2024: $1,407 · 2025: $95.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,243.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,952.10 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,898.88 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $963.56 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $693.94 | 2019-2024 | Dupixent |
| Insmed, INC. | $663.74 | 2019-2024 | Arikayce |
| United Therapeutics Corporation | $631.43 | 2019-2024 | Tyvaso, Remodulin, Orenitram |
| Mylan Specialty L.P. | $624.13 | 2019-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $483.35 | 2020-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.29 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $431.15 | 2022-2024 | |
| Grifols USA, LLC | $378.84 | 2019-2024 | Prolastin-C Liquid |
| Electromed, INC. | $346.99 | 2021-2023 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $299.78 | 2021-2024 | Glassia |
| Jazz Pharmaceuticals INC. | $260.96 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $238.94 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.